Observational studyRheumatology international2025
Long-term changes in Sjögren's disease: a 9-year prospective follow-up study from the SJOGRENSER Registry.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Practical management of Sjögren's disease in the era of new treatment options : Current value of available outcome parameters].Zeitschrift fur Rheumatologie · 2026Article
- Determinants and clinical correlates of minor salivary gland biopsy findings for suspected Sjögren disease: a single center retrospective analysis.Rheumatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of SjögrenSER Prospective (SjD-PROS) was to evaluate the improvement, stability or progression of SjD in clinical practice. SjD-PROS is an observational, longitudinal, multicenter study of SjD in Spain. Participants from the prior transversal phase were invited to a follow-up visit after 9.5 years. Data were collected via interviews and medical records. Variables were analyzed using means, medians and frequencies. Statistical associations were assessed using T student test, Kruskal-Wallis and the Chi-square test. We included 314 patients, 95% women (mean age of 66 years; mean disease duration of 17 years). At follow-up visit, the most frequent systemic manifestations were arthralgias (54%) and hematological involvement (49%), with arthralgias being significantly less frequent than at baseline visit (p < 0.001); the most affected organs were the lung (15.6%) and the kidney (11.5%). Half of the patients in SjD-PROS, had positive rheumatoid factor, 16% less than at baseline visit; β2-microglobulin was significantly elevated compared to baseline visit (62.5%, p < 0.001). Articular, pulmonary, hematological and biological domains of ESSDAI index showed the greatest changes, both in improvement and worsening, and the greatest activity. Systemic treatments use was significantly higher in patients showing activity in ESSDAI. This study offers valuable insights into the most variable clinical and serological manifestations throughout the course of SjD. ESSDAI domains showing the greatest changes reflected the greatest treatments needs. These findings allow for patient stratification based on phenotype, a crucial step in designing follow-up protocols.
Indexed as
Identifiers
40526294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.